Calliditas Therapeutics AB (CALT)
| Market Cap | 469.68M |
| Revenue (ttm) | 47,059 |
| Net Income (ttm) | -69.85M |
| Shares Out | 26.67M |
| EPS (ttm) | -2.88 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 66,216 |
| Open | 17.92 |
| Previous Close | 17.00 |
| Day's Range | 17.33 - 18.04 |
| 52-Week Range | 14.96 - 34.76 |
| Beta | 1.34 |
| Analysts | Strong Buy |
| Price Target | 51.80 (+194.2%) |
| Earnings Date | Nov 18, 2021 |
About CALT
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. The company's lead product candidate is Nefecon, a oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) was founded in 2004 and is headquartered in Stockholm, Sweden.
Analyst Forecast
According to 5 analysts, the average rating for CALT stock is "Strong Buy." The 12-month stock price forecast is 51.80, which is an increase of 194.15% from the latest price.
News
Calliditas Therapeutics: Q3 Earnings Insights
Calliditas Therapeutics (NASDAQ:CALT) reported its Q3 earnings results on Thursday, November 18, 2021 at 01:00 AM. Here's what investors need to know about the announcement.
Calliditas Therapeutics: Interim Report Q3, 2021
STOCKHOLM, Nov. 18, 2021 /PRNewswire/ -- "Following on from the positive top line read out of Part A our Phase 3 study, we initiated a structured process to select our commercial partner for Nefecon in ...
Calliditas announces poster presentations at ASN Digital Kidney Week 2021
STOCKHOLM, Nov. 3, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced upcoming presentations concerning Nefecon, its lead product can...
Calliditas Therapeutics' nomination committee for the AGM 2022
STOCKHOLM, Nov. 2, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ.) publishes the nomination committee's composition for the AGM in 2022.
Calliditas Takes 100% Control Of Genkyotex
Swedish drugmaker Calliditas Therapeutics AB (NASDAQ: CALT) has now taken complete control of Genkyotex after completing a centralized squeeze-out offer to all minority shareholders. Deal terms were not...
Calliditas announces acquisition of remaining Genkyotex minority shares
STOCKHOLM, Oct. 7, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company now controls 100% of the share capital of Genk...
Updated regulatory timeline for review of MAA in Europe
STOCKHOLM, Sept. 16, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas" or the "Company") (Nasdaq Stockholm: CALTX) (Nasdaq: CALT), a biopharma company focused on identifying, developi...
Calliditas Therapeutics Stock Falls As FDA Pushes Nefecon PDUFA Goal Date To December
The FDA has extended the PDUFA goal date for Calliditas Therapeutics AB's (NASDAQ: CALT) application seeking accelerated approval for Nefecon. Nefecon is an oral formulation targeting down-regulation of...
Number of shares and votes in Calliditas Therapeutics
STOCKHOLM, Aug. 31, 2021 /PRNewswire/ -- During August, the number of shares and votes in Calliditas Therapeutics AB (publ) has increased due to the directed share issue of 2,400,000 new shares that the...
Calliditas Therapeutics: Interim Report Q2, 2021
STOCKHOLM, Aug. 19, 2021 /PRNewswire/ -- "Following the filing for accelerated approval with the FDA in Q1, we filed our submission for conditional approval with EMA in May. Both FDA and EMA application...
Calliditas Therapeutics has resolved on a directed share issue in the amount of 2.4 million shares, raising proceeds ...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DIST...
Is a Surprise Coming for Calliditas (CALT) This Earnings Season?
Calliditas (CALT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Calliditas' Chronic Orphan Liver Disease Candidate Receives FDA Fast Track Tag
The FDA has granted Fast Track Designation to Calliditas Therapeutics AB's (NASDAQ: CALT) lead NOX inhibitor candidate setanaxib for primary biliary cholangitis (PBC). Setanaxib has previously been gran...
Calliditas Receives FDA Fast Track Designation for setanaxib in PBC
STOCKHOLM, Aug. 9, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the U.S. Food and Drug Administration (FDA) has granted Fa...
Calliditas Therapeutics and STADA partner to register and commercialize specialty therapy for IgA Nephropathy in Europe
STOCKHOLM and BAD VILBEL, Germany, July 21, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT), (Nasdaq Stockholm: CALTX) ("Calliditas") and STADA Arzneimittel AG ("STADA") announced today t...
Calliditas secures $75 million term loan facility
STOCKHOLM, July 15, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company has signed a loan agreement of up to the Euro...
Calliditas Announces Submission of Marketing Authorisation Application for Nefecon to the European Medicines Agency
STOCKHOLM, May 28, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company submitted a Marketing Authorisation Applicatio...
Calliditas Therapeutics to Present at Jefferies Virtual Healthcare Conference
STOCKHOLM, May 28, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that management will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2...
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
STOCKHOLM, May 27, 2021 /PRNewswire/ -- The following resolutions were passed at Calliditas Therapeutics AB (publ) ("Calliditas") annual general meeting held today, on May 27, 2021. Adoption of income s...
Interim Report Q1, 2021
STOCKHOLM, May 18, 2021 /PRNewswire/ -- Filing of New Drug Application submission to the FDA "Following the positive top line readout of our pivotal Phase 3 trial NefIgArd, which met both the primary an...
Calliditas Therapeutics to host conference call to provide Business Update for the first quarter of 2021
STOCKHOLM, May 14, 2021 /PRNewswire/ -- On May 18 th, 2021, Calliditas Therapeutics AB (publ) ("Calliditas") will publish its financial report for the first quarter of 2021, and at 2.30 pm CET will host...
Calliditas promotes Andrew Udell to President, North America
STOCKHOLM, May 3, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that former Head of North America Commercial, Andrew Udell, has ...
Calliditas Therapeutics AB: Change in financial calendar
STOCKHOLM, April 27, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) announces today that the Board has decided that the interim report for the first quarter 202...
Calliditas Therapeutics' 2020 Annual Report Published
STOCKHOLM, April 27, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2020 now is available at the company's website: w...
Notice of annual general meeting of Calliditas Therapeutics AB (publ)
STOCKHOLM, April 26, 2021 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB (publ), Reg. No. 556659-9766, with registered office in Stockholm, are summoned to the annual general meeting on ...